Results 31 to 40 of about 646,053 (288)

Systemic, Mucosal, and Memory Immune Responses following Cholera

Tropical Medicine and Infectious Disease, 2021
Vibrio cholerae O1, the major causative agent of cholera, remains a significant public health threat. Although there are available vaccines for cholera, the protection provided by killed whole-cell cholera vaccines in young children is poor.
Edward T. Ryan, Daniel T. Leung, Owen Jensen, Ana A. Weil, Taufiqur Rahman Bhuiyan, Ashraful Islam Khan, Fahima Chowdhury, Regina C. LaRocque, Jason B. Harris, Stephen B. Calderwood, Firdausi Qadri, Richelle C. Charles   +11 more
doaj   +1 more source

Vibrio cholerae, classification, pathogenesis, immune response, and trends in vaccine development

Frontiers in Medicine, 2023
Vibrio cholerae is the causative agent of cholera, a highly contagious diarrheal disease affecting millions worldwide each year. Cholera is a major public health problem, primarily in countries with poor sanitary conditions and regions affected by ...
David A. Montero, Roberto M. Vidal, Roberto M. Vidal, Juliana Velasco, Juliana Velasco, Sergio George, Yalda Lucero, Yalda Lucero, Leonardo A. Gómez, Leandro J. Carreño, Leandro J. Carreño, Richard García-Betancourt, Miguel O’Ryan   +12 more
doaj   +1 more source

Controlling endemic cholera with oral vaccines. [PDF]

PLoS Medicine, 2007
Although advances in rehydration therapy have made cholera a treatable disease with low case-fatality in settings with appropriate medical care, cholera continues to impose considerable mortality in the world's most impoverished populations ...
Ira M Longini, Azhar Nizam, Mohammad Ali, Mohammad Yunus, Neeta Shenvi, John D Clemens   +5 more
doaj   +1 more source

Cholera pulse vaccination: A possible elimination strategy for cholera in endemic countries

Indian Journal of Public Health, 2021
Cholera is a diarrheal disease causing major health issue in developing countries where it is endemic and causes outbreaks. India ranks first with an estimated 675,188 number of cases and 20,256 number of deaths annually with one-third of its population ...
Neelam Taneja, Swati Gupta, Jutang Babat Ain Tiewsoh, Sonakshi Srivastava   +3 more
doaj   +1 more source

Cholera vaccine clinical trials: A cross-sectional analysis of clinical trials registries

Human Vaccines & Immunotherapeutics, 2023
Cholera has been one of the world’s biggest public health challenges for centuries. The presence of this disease brings into focus the social determinants of health in different parts of the world.
Lindi Mathebula, Thobile Malinga, Mammekwa Mokgoro, Duduzile Ndwandwe, Charles S. Wiysonge, Glenda Gray   +5 more
doaj   +1 more source

Vaccination against cholera in Juba [PDF]

The Lancet Infectious Diseases, 2017
In an interesting Personal View, Lucy Parker and colleagues1 reported the difficulties regarding implementation of a reactive oral cholera vaccination (OCV) campaign during the 2015 cholera epidemic in Juba, South Sudan.1 They support the choice to address the global shortage of vaccines by providing just one dose to twice the number of people. However,
Rebaudet, Stanislas, Gaudart, Jean, Piarroux, Renaud   +2 more
openaire   +4 more sources

Oral vaccines for preventing cholera [PDF]

Cochrane Database of Systematic Reviews, 2010
This review is superseded by the published Cochrane Review, Saif‐Ur‐Rahman 2024 [https://doi.org/10.1002/14651858.CD014573], which considers only the oral killed vaccines because the live oral vaccines do not have World Health Organization (WHO) prequalification. Saif‐Ur‐Rahman 2024 also considered only currently available WHO pre‐qualified oral killed
Sinclair, David, Abba, Katharine, Zaman, K., Qadri, Firdausi, Graves, Patricia M.   +4 more
openaire   +4 more sources

Urban Cholera transmission hotspots and their implications for Reactive Vaccination: evidence from Bissau city, Guinea Bissau [PDF]

, 2012
Use of cholera vaccines in response to epidemics (reactive vaccination) may provide an effective supplement to traditional control measures. In Haiti, reactive vaccination was considered but, until recently, rejected in part due to limited global supply ...
Azman, A S, Banga, C N, Grais, R, Grenfell, B T, Lessler, J, Luquero, F J, Palma, P P, Rodrigues, A   +7 more
core   +5 more sources

Efficacy and Safety of Cholera Vaccines

Биопрепараты: Профилактика, диагностика, лечение, 2018
Cholera is an acute diarrheal disease caused by toxigenic strains of Vibrio cholerae O1 and O139 serogroups. It still remains a major  global healthcare problem.
A. A. Goryaev, L. V. Sayapina, Yu. I. Obukhov, V. P. Bondarev   +3 more
doaj   +1 more source

Evaluation and use of surveillance system data toward the identification of high-risk areas for potential cholera vaccination: a case study from Niger. [PDF]

, 2012
In 2008, Africa accounted for 94% of the cholera cases reported worldwide. Although the World Health Organization currently recommends the oral cholera vaccine in endemic areas for high-risk populations, its use in Sub-Saharan Africa has been limited ...
Ali Djibo, Augusto E Llosa, Bachir Mayana, D Sinclair, D Sur, DA Sack, Global Task Force on Cholera Control, Guidelines Working Group, IM Longini, J Guerra, JD Clemens, JL Deen, Jose Guerra, M Ali, M Enserink, M Jeuland, Mahamane L Manzo, Meeting of the Strategic advisory Group of Experts on immunization, R development Core Team, Rebecca F Grais, RI Glass, République du Niger, World Health Organization Regional Office for Africa and the Centers for Disease Control and Prevention   +22 more
core   +3 more sources